MediWound Ltd., a biopharmaceutical company, develops, manufactures and markets new and biotherapeutic solutions for tissue repair and regeneration. The company is headquartered in Yavne, Israel.
| Revenue (TTM) | $11.86M |
| Gross Profit (TTM) | $1.83M |
| EBITDA | $-30.75M |
| Operating Margin | -305.90% |
| Return on Equity | -72.40% |
| Return on Assets | -28.60% |
| Revenue/Share (TTM) | $0.96 |
| Book Value | $2.76 |
| Price-to-Book | 4.88 |
| Price-to-Sales (TTM) | 14.62 |
| EV/Revenue | 12.4 |
| EV/EBITDA | -6.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -45.80% |
| Shares Outstanding | $13.01M |
| Float | $8.87M |
| % Insiders | 16.66% |
| % Institutions | 55.48% |
Volatility is currently expanding
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has entered into an underwriting agreement with H.C.
MediWound to Report Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, November 12 th at 8:30 a.m. Eastern Time YAVNE, Israel, October 29, 2026 -- MediWound Ltd.
Independent DSMB Recommends MediWound's EscharEx ® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB) completed its pre-specified periodic safety review of the ongoing Phase III VALUE study evaluating the safety and efficacy of EscharEx® in patients with venous leg ulcers (VLU).
MediWound to Present at the H.C. Wainwright 28 th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd.
MediWound NASDAQ: MDWD reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid burn treatment.
MediWound (MDWD) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $1.23 per share a year ago.
EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid ® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26 Million Reaffirmed Conference Call Today at 8:30 a.m. Eastern Time YAVNE, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd.
MediWound to Report Second Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, August 13 at 8:30 a.m. Eastern Time YAVNE, Israel, July 29, 2026 -- MediWound Ltd.
MediWound NASDAQ: MDWD reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MDWD and any ticker you trade — then tracks every position and per-strategy win rate.
